Clinical trial · Observational
Real World Outcomes Using Novel Agents for AML in the UK
Real World Outcomes Using Novel Agents for Acute Myeloid Leukaemia in the United Kingdom
NCT05312112CI-TRIAL-00064388unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gilteritinib | Drug | Gilteritinib | ALIAS |
| Venetoclax | Drug | Venetoclax | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Venetoclax
- description
- Venetoclax in newly diagnosed AML
- interventionNames
- Drug: Venetoclax
- label
- FLT3 inhibitors
- description
- FLT3 inhibitors including gilteritinib in relapsed AML
- interventionNames
- Drug: Gilteritinib
Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- 1 year
- description
- Overall survival measured from time of treatment initiation
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Venetoclax cohort Inclusion criteria 1. Newly diagnosed acute myeloid leukaemia 2. No prior therapies for AML, apart from hydroxyurea (or similar) for cytoreduction. Previous treatments for MDS or other conditions are allowed 3. Treated with venetoclax in combination with either azacitidine or LDAC No exclusion criteria Gilteritinib/FLT3 cohort Inclusion criteria 1. Relapsed acute myeloid leukaemia, including molecular relapse 2. Treated with FLT3 inhibitor No exclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.